Who Was Not in the Study? Open Questions in Clinical Research Generalizability and Causal Inference

Clinical medicine runs on associations. A biomarker correlates with disease severity. An infection precedes an autoimmune diagnosis. A medication class appears linked to an adverse outcome in elderly patients. These findings accumulate in the literature and gradually shape practice — sometimes before anyone has checked whether the relationship holds outside the population, geography, or study design where it was first observed.

The question of generalizability is not new. Every methods section acknowledges it, usually in a limitations paragraph near the end. What is less often confronted is the specific cost of deferred validation: when single-center studies from specialized tertiary hospitals become the evidence base for global clinical guidelines, when exposure-response thresholds derived from one climate zone get adopted in others, when causal claims are inferred from cross-sectional designs that cannot, by construction, establish causality.

The 2022–2026 literature contains a recurring pattern of researchers explicitly acknowledging that the relationship they documented is real within their cohort and may not be real anywhere else. This post identifies six of those acknowledgments, drawn from primary literature across cardiology, obstetrics, rheumatology, and environmental medicine, and asks what it would actually take to resolve them.

Does serum uric acid independently predict heart failure severity across all patient populations?

The relationship between serum uric acid concentration and chronic congestive heart failure severity is biologically plausible: uric acid is a downstream product of purine catabolism, elevated in states of increased oxidative stress and inflammation, both of which characterize failing myocardium. Alshamari, Kadhim, and AL-Mohana (2022) examined this relationship in a cohort from Kufa University Hospital, documenting a correlation between uric acid levels and functional class — but the study population's demographic characteristics, including age range, comorbidity profile, race, and ethnicity, are not described in the published record, and the authors themselves identify validation across African, Asian, and Caucasian cohorts in different geographic settings as required before the finding can be considered generalizable (10.25122/jml-2022-0068).

The gap matters clinically. Serum uric acid as a heart failure biomarker would be attractive in resource-limited settings where standard cardiac biomarkers like BNP and troponin are expensive or unavailable. But deploying a biomarker whose calibration was established in one ethnic cohort at a single Iraqi hospital — without cross-population validation — is a different proposition than deploying one whose predictive performance has been confirmed across demographically distinct groups. Loomba et al. (2026) separately flag the absence of systematic long-term outcome data in cardiac patients receiving novel interventions, underscoring a broader pattern in which promising clinical relationships accumulate faster than validation evidence (10.1007/s40746-026-00371-x). The uric acid question is a specific instance of that general problem: a clinically actionable biomarker relationship that remains anchored to its cohort of origin.

Can photodynamic therapy's antiviral effects be standardized for community ENT practice?

Photodynamic therapy has accumulated evidence across ENT applications — head and neck tumors, chronic rhinosinusitis, recurrent tonsillitis. Mierzejewska et al. (2026) review current evidence for PDT in otorhinolaryngology and identify promising antiviral effects including activity against SARS-CoV-2, but identify a specific open question: whether PDT can function as a reliable infection control modality during viral epidemics in community ENT practice, as opposed to controlled experimental conditions (10.12775/qs.2026.52.69472).

The gap between laboratory antiviral demonstration and community clinical deployment involves multiple validation steps that the review acknowledges have not been completed. Dose standardization, delivery device variability, the range of respiratory viruses against which efficacy must be demonstrated, and the practical constraints of community ENT settings — staffing, equipment access, patient throughput — all remain outside the existing evidence base. This is a common structure in therapeutic validation: promising antiviral effects demonstrated under controlled conditions, no established protocol for consistent deployment in the heterogeneous environments where most patients receive care. Until multi-site community trials are conducted using standardized PDT protocols against a defined panel of clinically relevant viruses, the antiviral indication remains a laboratory observation rather than a clinical option.

What does cross-sectional design systematically miss when studying medication-related outcomes?

Three separate papers in the 2022–2025 literature acknowledge the same structural limitation with different clinical content. Bermudez-Villalpando et al. (2025) examine benzodiazepine use and fall risk in older adult patients, noting explicitly that further studies are required to establish causality between external factors related to fall sites and actual fall occurrence — the cross-sectional snapshot cannot distinguish whether benzodiazepines cause falls or whether patients prone to falls are prescribed benzodiazepines for conditions that independently impair gait (10.26420/jfammed.2025.1377). Faisal et al. (2025) study corticosteroid dosage and depression and anxiety symptoms in systemic lupus erythematosus, with the cross-sectional design preventing causal inference about whether steroid exposure produces psychological symptoms or whether sicker patients receive higher doses and also have worse psychological outcomes (10.37897/rjr.2025.3.4). Cigiloglu et al. (2022) examine polypharmacy and depression in older individuals with the same retrospective limitation (10.5152/eurjther.2022.21040).

The accumulation of cross-sectional associations in geriatric pharmacology and rheumatology reflects the structural difficulty of running prospective randomized trials in populations taking medications for serious chronic conditions. But the practical consequence is a literature that documents correlations between drug exposure and adverse outcomes while remaining unable to tell clinicians whether the drug causes the outcome or whether the severity of the underlying disease causes both. This distinction matters most when the management decision is whether to reduce or discontinue a medication that may itself be controlling a dangerous disease process. Without prospective cohort data that tracks patients across medication changes over time, the association literature will continue to be clinically suggestive without being clinically actionable.

What causal mechanisms connect acute infection to persistent autoimmune dysfunction?

Graziade et al. (2022) present a case of multiple autoimmune syndrome following SARS-CoV-2 infection — the patient developed both systemic lupus erythematosus and mixed connective tissue disease post-COVID — and identify the limited documentation of relationships between COVID-19 infection and rheumatic autoimmune diseases as a specific gap the field needs to close (10.52768/2766-7820/2108). The causal chain is plausible: molecular mimicry between viral antigens and self-antigens, or bystander activation of autoreactive lymphocytes during viral clearance. But case reports and small series do not establish mechanism, and the mechanistic question — which viral proteins trigger which autoimmune pathways, in which patients with which genetic predispositions — remains open.

A complementary gap appears in sepsis research. Li et al. (2026) find elevated growth differentiation factor-15 in sepsis patients and document clinical associations with disease severity, but the study explicitly does not establish a causal or predictive role for GDF-15: the circulating levels track integrated physiological stress without the authors being able to determine whether GDF-15 is a driver or a consequence of the dysregulated immune response (10.3389/fcell.2026.1789747). Both papers illustrate the same epistemological gap: infections produce measurable molecular and immunological changes, but tracing those changes to specific functional outcomes via validated causal pathways remains largely undone. The path from observed association — infection precedes autoimmune diagnosis, GDF-15 rises during sepsis — to mechanistic explanation requires cell-line work, animal models, and ultimately prospective human studies with adequate follow-up periods. None of those steps can be shortcut by accumulating more cross-sectional observations.

Do climate-derived exposure-response thresholds translate across geographies?

Qiu et al. (2026) analyze the relationship between autumn-winter wind speed, low temperatures, and acute coronary syndrome incidence in a five-year single-center study in Beijing, finding significant associations and identifying wind chill as a factor in ACS onset. The paper explicitly recommends that regions outside temperate Köppen climate zones establish their own exposure-response curves through multi-city replications rather than adopting Beijing-derived thresholds (10.1038/s41598-025-34432-2).

The recommendation is methodologically correct and practically difficult. Multi-city replication studies in environmental cardiology require coordinated data collection across health systems in different countries, standardized ACS case definitions, and comparable meteorological datasets. The cities and populations most likely to have different exposure-response relationships from Beijing — in sub-Saharan Africa, South Asia, Middle Eastern desert climates — are also the populations least likely to have the research infrastructure to run the replication studies. Atta et al. (2017) encountered a structurally analogous limitation in epidemiology: a single Egyptian governorate's hemodialysis data could not support national prevalence estimates without multi-center replication across other governorates, with the geographic specificity of the cohort directly limiting the scope of inference (10.21474/ijar01/2899). Geographically confined studies cannot support geographically general conclusions, but the extension studies are expensive and take years to organize — during which time the single-center findings may be the only data available to inform local clinical decision-making.

What does omitting placental pathological examination hide about maternal-fetal infection outcomes?

Zheng et al. (2026) describe a case of Chlamydia psittaci pneumonia diagnosed in the second trimester of pregnancy, treated successfully with azithromycin, and resulting in term delivery without apparent neonatal harm. The paper explicitly identifies the absence of placental pathological examination as a major methodological limitation: without tissue evidence of placental involvement, the authors cannot confirm whether vertical transmission occurred, what the infection route was, or whether the favorable neonatal outcome reflects absence of placental infection or effective immune containment of an infection that did occur (10.3389/fphar.2026.1780706).

This is a clinically consequential gap. Case reports of rare infections in pregnancy are often the only evidence available to guide management decisions, because randomized trials in pregnant populations are rarely feasible. When those case reports lack pathological confirmation of the proposed causal mechanism — in this instance, that azithromycin prevented vertical transmission by clearing a placental infection — they cannot distinguish between effective treatment and an infection that was never going to cross the placental barrier. Clinicians reading such reports are making inferences about mechanism from outcome data, which is precisely the inferential move that case-report designs cannot support. Systematic collection of placental pathology in cases of atypical respiratory infection during pregnancy would convert a recurring single-case inference problem into a cumulative evidence base. The barrier is not methodological but logistical: placental examination requires coordination between obstetric, neonatal, and pathology teams at the time of delivery, and in cases of favorable outcome that coordination is often not prioritized.

The six questions documented here are not rhetorical gaps or theoretical limitations. Each has a concrete empirical answer that would change how biomarkers are deployed, how medications are managed, how infection-driven autoimmunity is studied, and how geographic confounders are handled in environmental medicine. None of those answers exists yet. The research designs that would produce them — prospective multi-site cohorts, mechanistic studies following acute infection into immune dysregulation, replication trials in demographically distinct populations, systematic pathological sampling in maternal infection cases — are demanding but not impossible. What they require, above all, is a field willing to treat the generalizability question as a first-class research problem rather than a limitation to acknowledge and defer.